Nombre total de rapports de communication : 0
Rapports mensuels de communications au cours des 6 derniers mois : 0
Objets | Détails | Catégories |
---|---|---|
Santé
|
Advocating for amendments to the Controlled Drugs and Substances Act to allow for the regulated use of psychedelics in therapeutic settings. This includes lobbying for policy development to support clinical trials and research into the therapeutic potential of substances like psilocybin and MDMA for treating mental health disorders.
|
Proposition législative, Projet de loi ou résolution
|
Santé
|
Advocating for comprehensive mental health policy reform and resource allocation.
Evaluation and optimization of existing mental health services and facilities
Improved access to mental health care across diverse populations
Integration of mental health services within the broader healthcare system
Sustainable funding models for mental health programs and infrastructure
|
Subvention, Contribution ou autre avantage financier, Proposition législative, Projet de loi ou résolution, Politique ou Programme, Règlement
|
Santé
|
Engaging with policymakers to improve mental health care policies, focusing on integrating innovative treatments, including psychedelic-assisted therapies, into the national mental health care framework. Emphasis on funding, access, and training programs for healthcare professionals.
|
Politique ou Programme, Subvention, Contribution ou autre avantage financier
|
LaRubie.com engages in advocacy and policy consultation for mental health and psychedelic research. We focus on advancing legislative and regulatory frameworks that support the responsible integration of psychedelics into mental health practices. Our activities include policy development, educational outreach, and strategic guidance to stakeholders within the mental health and psychedelic sectors.
Stephanie Ghio, President
Adresse :
3045 place guillemette
apt 137
Laval, QC H7P 5N9
Canada
Numéro de téléphone :
514-619-4965
LaRubie n'est pas une filiale d'une société mère.
LaRubie ne possède aucune filiale qui pourrait être directement intéressée au résultat de l'engagement